New developments in the medical treatment of Cushing's syndrome
Endocrine - Related Cancer , Volume 19 - Issue 6
Cushing's syndrome (CS) is a severe endocrine disorder characterized by chronic cortisol excess due to an ACTH-secreting pituitary adenoma, ectopic ACTH production, or a cortisol-producing adrenal neoplasia. Regardless of the underlying cause, untreated CS is associated with considerable morbidity and mortality. Surgery is the primary therapy for all causes of CS, but surgical failure and ineligibility of the patient to undergo surgery necessitate alternative treatment modalities. The role of medical therapy in CS has been limited because of lack of efficacy or intolerability. In recent years, however, new targets for medical therapy have been identified, both at the level of the pituitary gland (e.g. somatostatin, dopamine, and epidermal growth factor receptors) and the adrenal gland (ectopically expressed receptors in ACTH-independent macronodular adrenal hyperplasia). In this review, results of preclinical and clinical studies with drugs that exert their action through these molecular targets, as well as already established medical treatment options, will be discussed.
|Endocrine - Related Cancer|
|Organisation||Department of Internal Medicine|
van der Pas, R, de Herder, W.W, Hofland, L.J, & Feelders, R.A. (2012). New developments in the medical treatment of Cushing's syndrome. Endocrine - Related Cancer (Vol. 19). doi:10.1530/ERC-12-0191